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Recently, a rare activating mutation of AKT1 (E17K) has been reported in breast, ovarian, and colorectal cancers. However, analogous
activating mutations in AKT2 or AKT3 have not been identified in any cancer lineage. To determine the prevalence of AKT E17K
mutations in melanoma, the most aggressive form of skin cancer, we analysed 137 human melanoma specimens and 65 human
melanoma cell lines for the previously described activating mutation of AKT1, and for analogous mutations in AKT2 and AKT3. We
identified a single AKT1 E17K mutation. Remarkably, a previously unidentified AKT3 E17K mutation was detected in two melanomas
(from one patient) as well as two cell lines. The AKT3 E17K mutation results in activation of AKT when expressed in human
melanoma cells. This represents the first report of AKT mutations in melanoma, and the initial identification of an AKT3 mutation in
any human cancer lineage. We have also identified the first known human cell lines with naturally occurring AKT E17K mutations.
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Melanoma is the most aggressive form of skin cancer, and patients
with metastatic disease have a dismal prognosis that is not
significantly improved with systemic therapies (Tsao et al, 2004).
The pattern of genetic alterations in this disease suggests that
activation of kinase signalling pathways has an important function in
the initiation and pathophysiology of melanoma. BRAF,as e r i n e -
threonine kinase in the RAS/RAF/MAPK signalling cascade, is
mutated in 60–70% of melanomas and, to date, represents the most
common mutation in this disease (Davies et al, 2002; Curtin et al,
2005). Over 80% of the BRAF mutations involve a missense mutation
that results in the substitution of glutamic acid for valine at amino
acid 600 (V600E). Expression of this mutant form of BRAF in vitro
results in constitutive activation of MAPK (Davies et al,2 0 0 2 ) .T h e
PI3K/AKT pathway may also have an important function in
melanoma. NRAS, which activates both the RAS/RAF/MAPK and
the PI3K/AKT signalling pathways, is mutated in approximately 15%
of melanoma tumours and cell lines (Goydos et al, 2005; Goel et al,
2006). Loss of function of the tumour suppressor PTEN, which
results in activation of the PI3K/AKT pathway, occurs in 10–30% of
melanomas, frequently concurrent with activating BRAF mutations
(Tsao et al, 1998; Zhou et al, 2000; Haluska et al, 2006). Activating
mutations of PIK3CA, which encodes the p110a catalytic subunit of
PI3Ks, have been detected with significant frequency in colon, breast,
and ovarian cancers, but appear to be rare in melanoma (1.5%)
(Curtin et al, 2006; Omholt et al, 2006).
AKT/PKB, a serine-threonine kinase, is a key downstream
effector of PI3K-mediated signalling (Downward, 2004). Recently,
a point mutation in AKT1 was identified in breast, ovarian, and
colon cancers (Carpten et al, 2007). This mutation (E17K)
increases recruitment of AKT1 to the membrane, increases AKT1
phosphorylation and activity, transforms Rat1 fibroblasts, and
induces leukaemia in transgenic mice (Carpten et al, 2007). No
melanoma specimens were examined in that study. To determine
whether AKT E17K mutations occur in melanoma, we used a mass
spectroscopy-based approach designed to detect single-nucleotide
polymorphisms (SNPs) to determine the frequency of this
activating mutation in AKT1, AKT2, and AKT3 isoforms in a large
panel of human melanoma specimens and human cell lines.
MATERIALS AND METHODS
Clinical specimens
The OCT-embedded frozen clinical specimens were obtained from
the Melanoma Informatics, Tissue Resource and Pathology Core at
The University of Texas MD Anderson Cancer Center under an
Institutional Review Board approved protocol (PI- JEG). The H&E
slides were reviewed by an experienced dermatopathologist (VGP
or AJFL) to identify specimens with regions enriched for viable
tumour cells. These slides were used as a guide to macrodissect the
OCT block and isolate the selected tumour-enriched region.
Ten- to twenty-micrometre shears were prepared at  201C and
then were stored at  801C for molecular studies. An additional
H&E slide was made after all shears were prepared and was
reviewed by an experienced dermatopathologist to confirm 470%
tumour content in the section used. Genomic DNA was isolated
using the QIAmp DNA Mini kit (Qiagen, Valencia, CA, USA)
according to the manufacturer’s guidelines.
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Human melanoma cell lines were grown under normal tissue
culture conditions in RPMI supplemented with fetal calf serum.
Cell pellets were isolated, and DNA was extracted using the QIAmp
DNA Mini kit (Qiagen) according to the manufacturer’s guidelines.
Mass spectroscopy-based AKT mutation detection
A mass spectroscopy-based approach evaluating SNPs was used to
detect the AKT1 E17K mutation, and mutations in the equivalent
sites of AKT2 and AKT3 (Thomas et al, 2007). Polymerase chain
reaction (PCR) and extension primers for AKT1, AKT2, and AKT3
were designed using Sequenom Inc. (San Diego, CA, USA) Assay
Design. PCR-amplified DNA was cleaned using EXO-SAP (Seque-
nom), primer extended by IPLEX chemistry, desalted using Clean
Resin (Sequenom), and spotted onto Spectrochip matrix chips
using a nanodispenser (Samsung). Chips were run in duplicate on
a Sequenom MassArray MALDI-TOF MassArray system. Seque-
nom Typer Software and visual inspection were used to interpret
mass spectra. Reactions where more than 15% of the resultant
mass ran in the mutant site in both reactions were scored as
positive. All mutations were confirmed by Sanger sequencing in
the MD Anderson Cancer Center Support Grant-supported
sequencing core.
Plasmids
Human AKT3 cDNA cloned into the pcDNA3 vector with a HA-tag
at the N-terminus was generously provided by Dr Yiling Lu (MD
Anderson Cancer Center). The G-A point mutation that results
in the substitution of lysine for glutamic acid at amino acid 17 was
introduced using Quick-Change Site-Directed Mutagenesis
(Stratagene, La Jolla, CA, USA). The nucleotide change was
confirmed by direct sequencing.
Transient transfection and western blotting
The A375 human melanoma cell line was seeded the day before
transfection on six-well tissue culture plates. Cells were transfected
with indicated plasmids and Fugene HD Transfection Reagent
(Roche, Indianapolis, IN, USA) as per the manufacturer’s
instructions. Eight hours after transfection the media was replaced.
After 48h transfection, media was replaced with media containing
either 5 or 0% serum (‘Serum-free’). Twenty-four hours later the
cells were harvested, washed with PBS, and resuspended in lysis
buffer containing 1% Triton X-100, 50mm HEPES, pH 7.4, 150mM
NaCl, 1.5mM MgCl2,1 m M EGTA, 100mM NaF, 10mM Na
pyrophosphate, 1mM Na3VO4, 10% glycerol, and supplemented
with complete Protease Inhibitor Cocktail tablet (Roche). Protein
isolation and western blotting were performed using the standard
techniques (Hennessy et al, 2007). Antibodies against HA tag
(Covance, Princeton, NJ, USA), Phospho-AKT Ser473 (C termi-
nus), Phospho-AKT Thr308 (activation loop), and AKT3
(Cell Signaling Technology, Danvers, MA, USA) were used. The
Phospho-AKT antibodies, which are designated above by the
relevant residues in AKT1, also recognise the corresponding
residues in AKT2 (Ser474, Thr309) and AKT3 (Ser472, Thr305).
RESULTS
Detection of AKT1 E17K and AKT3 E17K mutations in
melanoma
We analysed melanoma clinical specimens for the presence of
mutations in AKT1, AKT2, and AKT3 that result in the E17K
mutation identified previously in breast, ovarian, and colorectal
cancers. We used mass spectroscopy-based mutation detection,
which previously has been demonstrated to be a sensitive method
for detecting specific point mutations in clinical specimens and
cell lines (Thomas et al, 2007). Genomic DNA was analysed from
137 clinical specimens. Specimens were primarily from metastatic
lesions, including soft tissue (n¼16), lymph nodes (n¼77), and
parenchymal metastases (n¼28); primary melanomas (n¼16)
were also analysed. We identified two lymph node metastases
(from a single patient) that had the AKT3 E17K mutation
(Figure 1A). This mutation was not present in the DNA from
normal tissue of the same patient (Supplementary Figure 1). One
lymph node metastasis from a different patient harboured the
AKT1 E17K mutation. The AKT3 and AKT1E17K mutations were
confirmed by conventional Sanger sequencing (Figure 1B, and
Supplementary Figure 2).
We performed a similar analysis on genomic DNA isolated from
65 human melanoma cell lines (Supplementary Figure 3). We did
not identify any cell lines with AKT1 E17K or AKT2 E17K
mutations. However, we identified two cell lines with AKT3 E17K
mutations, WM46 and D40. Both cell lines were derived from
metastatic lesions. It is unlikely that these cell lines were cross-
contaminated or originated from the same patient, as they were
derived in laboratories in different hemispheres, and the cell lines
differed in the genetic sequences for other genes, including MC1R
and CDK4 (MAD and KS-H, unpublished data) (Landi et al, 2006).
Activation of AKT3 by the E17K mutation
Previous studies demonstrated that expression of AKT1 E17K
protein in NIH 3T3 cells increased AKT phosphorylation in those
cells (Carpten et al, 2007). To determine whether the AKT3 E17K
mutation results in a similar phenotype, we generated mammalian
expression vectors with HA-tag-fused AKT3 (wild type) and
HA-tag-fused AKT3 E17K. These vectors, as well as empty control
vector, were transiently transfected in the A375 human melanoma
cell line. The A375 cell line was derived from a lymph node
metastasis, the same anatomic setting as the specimens that
harboured the AKT3 E17K mutation(Kozlowski et al, 1984). The
A375 cells do not have an activating mutation of AKT, PIK3CA,o r
N-ras, and express PTEN protein (MAD and KS-H, unpublished
data). Expression of AKT3 E17K in A375 cells increased AKT
phosphorylation, as compared to transfection with the control
vectors or wild-type AKT3, under normal tissue culture conditions
(Figure 1, Panel C). Similar results were also seen when the cells
were grown in the absence of growth factors (Supplementary
Figure 4).
DISCUSSION
The PI3K signalling pathway is a critical regulator of many cellular
processes that contribute to the aggressive nature of cancer,
including proliferation, survival, invasion, and angiogenesis
(Hennessy et al, 2005). We sought to determine if the recently
identified activating mutation (E17K)i nAKT1, which was initially
detected in breast, colorectal, and ovarian cancers, and more
recently in lung cancer, occurs in melanoma tumours and cell lines
(Carpten et al, 2007; Kim et al, 2008; Malanga et al, 2008). In this
study, we identified the same AKT1 E17K mutation reported
previously in other cancers in the tumour from a melanoma
patient. We also identified the analogous E17K mutation in AKT3
in two different tumours (from the same patient) and in two
human melanoma cell lines. Two previous studies failed to detect
AKT3 mutations in clinical specimens of breast (n¼154), colo-
rectal (n¼155), ovarian (n¼50), gastric (n¼180), hepatocellular
carcinoma (n¼68), non-small cell lung cancer (n¼157), and adult
acute leukaemias (n¼129) (Carpten et al, 2007; Kim et al, 2008).
We have analysed an additional 547 primary breast cancers
without detecting AKT2 or AKT3 E17K mutations (Stemke-Hale
AKT3 mutations in melanoma
MA Davies et al
1266




















set al, 2008). Thus, this study represents the first report of an AKT3
mutation in human cancer.
Normal tissue from the patient with the AKT3 E17K mutation
failed to show evidence of this mutation (Supplementary Figure 1).
Thus, it is likely that the mutation was somatically acquired and
was not present in the germline. Unfortunately, DNA was not
available from the primary tumour of this patient, so it is unknown
if the mutation was present only in metastases. Of note, in both of
the tumour samples from this patient the observed prevalence of
the AKT3 E17K mutation was B30% (Figure 1A), meaning that
B60% of the analysed cells harbour the mutation if it is
heterozygous. Visual review by an experienced dermatopathologist
(AJFL) of H&E slides of these samples determined that the
percentage of tumour cells in the specimens was close to 80%. It
could be that only a portion of the tumour cells had the AKT3
mutation. Another explanation is that the lower percentage of
tumour cells could be because of smaller infiltrating lymphocytes
or other contaminating non-tumour cells that were in the deeper
cuts used to extract DNA but not readily apparent in the H&E
stain. Alternatively, the reason might be technical differences due
to PCR amplification biases or because higher mass ions are
discriminated against each other.
The discovery of an AKT3 mutation in melanoma is consistent
with previous data that suggest that this isoform of AKT may be
particularly critical in this cancer. Stahl et al (2004) found that
AKT3 protein, but not AKT1 or AKT2 protein, was increased in
melanoma cell lines when compared to normal melanocytes.
Transfection of siRNA against each AKT isoform in three different
melanoma cell lines demonstrated that the AKT3 isoform was
responsible for the majority of phosphorylated AKT in those cells
(Stahl et al, 2004). While previous studies of small numbers of
melanomas (n¼20 and n¼16, respectively) failed to identify
mutations in AKT (Waldmann et al, 2001, 2002), copy-number
increases of the region of chromosome 1 where AKT3 is located
have been reported (Thompson et al, 1995; Bastian et al, 2000;
Curtin et al, 2005).
It will be important to determine the functional significance of
the AKT3 E17K mutation. Preclinical models have demonstrated
that the isoforms of AKT may have markedly different effects on
cellular behaviours, including invasiveness and metastatic poten-
tial (Hutchinson et al, 2004; Irie et al, 2005). Others have
demonstrated that although AKT1, AKT2, and AKT3 have several
shared substrates, there are also proteins that are selectively
regulated by individual isoforms (Brognard et al, 2007). A critical
finding in the data presented here is the identification of two
human cancer cell lines with the AKT3 E17K mutation. To date, we
have tested a total of 178 human cancer cell lines for AKT E17K
mutations, including the entire NCI60 cell line collection, as well as
additional breast (n¼41) and ovarian (n¼27) cancer cell lines
(KS-H, not presented). WM46 and D40 were the only cell lines
found to harbour the E17K mutation in any AKT isoforms, and to
our knowledge are the first human cell lines identified with any
AKT mutation. These cell lines can be utilised to examine the
function of the AKT3 E17K mutant protein in a cellular setting in
















































Figure 1 AKT3 E17K mutation in melanoma. (A) Mass spectroscopy-based detection of AKT3 E17K mutation in a human melanoma clinical specimen.
Peaks correlating with wild-type AKT3 (‘1’) and mutant AKT3 (‘2’) are indicated. (‘3’¼predicted mass of unincorporated primer). Only the wild-type peak
was seen in normal tissue from the same patient (Supplementary Figure 1). (B) Confirmatory Sanger sequencing of tumour analysed by mass spectroscopy-
based method in (A). The missense substitution resulting in the E17K mutation is indicated with an arrow. (C) Western blotting analysis of A375 human
melanoma cells transfected with empty control vector (‘pcDNA3’), HA-tagged wild-type AKT3 (‘HA-AKT3’), and HA-tagged mutant AKT3 (‘HA-AKT3
E17K’). Results shown are for cells growing under normal tissue culture conditions.
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